Multiple Myeloma Treatment Preference Study

Incorporating patient values into health outcomes is known as Patient Value Mapping (PVM). CaPPRe are experts in PVM utilising discrete choice experiments (DCEs) and work closely with industry, academia and government to encourage patient involvement in healthcare decision making. 

In addition to our work in PVM CaPPRe conduct a number of research projects involving other stakeholders in the treatment decision process, including carers and healthcare professionals. One such study was conducted during 2016-17 regarding treatment preferences for Multiple Myeloma (MM) involving patients, carers, physicians and nurses completing an online survey including a DCE component.

At present, MM can be treated with several classes of treatments including immunomodulators, proteasome inhibitors, monoclonal antibodies and others [1, 2]. These treatments differ with respect to clinical outcomes such as the average length of survival and side effects, as well as non-clinical aspects such as the mode and frequency of administration and whether it is used as a therapy on its own or in combination with other therapies. Patients, carers, physicians and nurses may have different preferences for treatments based on these treatment characteristics.

Given the interaction and involvement of the care team with the patient, this study quantified treatment preferences and the alignment of treatment preferences for MM patients and the care team (carers, physicians and nurses).  Discrete choice experiments (DCEs) were used to empirically quantify preferences for treatment. DCEs are increasingly used to quantify patient and other stakeholder preferences for treatments in a broad range of diseases [3-5]and allow for an understanding of the underlying characteristics, or attributes, of treatment that influence patient preferences. This was the first study to examine treatment preference alignment between MM patients and the carers, physicians and nurses involved in their care and is clinically important in the care and management of patients diagnosed with MM.

With the support of Myeloma Australia, this study was jointly sponsored by multiple pharmaceutical manufacturers who are interested in treatment preferences of MM patients.  Results will be published in 2018.

References

1.         Hari P: Recent advances in understanding multiple myeloma. Hematology/Oncology and Stem Cell Therapy 2017.

2.         Naymagon L, Abdul-Hay M: Novel agents in the treatment of multiple myeloma: a review about the future. Journal of Hematology & Oncology 2016, 9:52.

3.         Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, Johnson FR: Conjoint analysis applications in health - how are studies being designed and reported? The Patient 2010, 3(4):249-256.

4.         Bridges JFP, Kinter ET, Kidane L, Heinzen RR, McCormick C: Things are Looking up Since We Started Listening to Patients. The Patient: Patient-Centered Outcomes Research 2008, 1(4):273-282.

5.         Lancsar E, Louviere J: Conducting Discrete Choice Experiments to Inform Healthcare Decision Making. PharmacoEconomics 2008, 26(8):661-677.